Unicycive Therapeutics Inc (UNCY)

$6.83 -0.18 (-2.57%)
Market Cap 146.78M
Revenue (ttm) 0.00
Net Income (ttm) -36.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 7.03
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 382,700
Avg Vol 565,998
Day's Range N/A - N/A
Shares Out 21.49M
Stochastic %K 48%
Beta 1.82
Analysts Strong Sell
Price Target $46.50

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, li...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 351 4495
Address:
4300 El Camino Real, Suite 210, Los Altos, United States
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 13 at 7:56 PM
$UNCY UNCY analyst coverage snapshot (with creds): • Benchmark — Bruce David Jackson: Buy, PT $21 (Sep 15, 2025) • Guggenheim — Vamil Kishore Divan, M.D.: Buy, PT $46 (Dec 30, 2025) • H.C. Wainwright — Ramakant(h) Swayampakula, M.B.A., Ph.D.: Buy, PT $22 (Oct 29, 2025) • Lucid — Elemer Piros, Ph.D.: Buy, PT $63 (Nov 12, 2025) • NOBLE — Robert Michael LeBoyer: Outperform, PT $60 (Jan 30, 2026) • WestPark — Ed Arce: Buy, PT $72 (initiated Feb 19, 2026)
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 13 at 7:33 PM
$UNCY Continues to be overhead supply between $7 and $7.30. I expect there is more above that. Curious, has anyone seen data around the amount of accumulation at this level and higher?
0 · Reply
Mtango
Mtango Mar. 13 at 4:38 PM
$UNCY I spent over 3h using AI to generate the investment thesis in the post below. I welcome feedback on the bearish and bullish arguments. https://www.reddit.com/r/UNCY/comments/1rssasq/uncy_an_aigenerated_investment_thesis/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
1 · Reply
Mtango
Mtango Mar. 13 at 3:17 PM
$UNCY $UNCY TDAPA Risk Nobody’s Talking About Everyone assumes OLC gets TDAPA after approval. But there’s a real question about whether it qualifies under CMS rules. Under 42 CFR §413.234(e), drugs in an existing ESRD PPS functional category (which phosphate binders are) are EXCLUDED from TDAPA if their NDA is classified as Type 3 (new dosage form) or Type 5 (new formulation). OLC is a 505(b)(2) referencing Fosrenol. It shares substantially the same label. The approval is based on a bioequivalence study bridging to Fosrenol. The main difference? Smaller pills you swallow instead of chew. That screams Type 3 or Type 5 classification from FDA. (Continued below)
1 · Reply
zawojak
zawojak Mar. 13 at 12:04 PM
$UNCY possible $15 by december guys !!
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 12 at 11:36 AM
$CELC $UNCY $AXSM im coming
0 · Reply
AlbertSan
AlbertSan Mar. 11 at 11:03 PM
$UNCY ready with 20 calls for Jul
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 10 at 6:56 PM
$UNCY This level may take a bit to work out. Between 6-9-2025 and 6-24-2025 there were 8,678,970 shares bought above this price right before it dropped and CRL occurred… The sells each time we breach $7 are largely those of them who held on unloading to break even. On one side it is positive that we are placing the shares into stronger hands. It builds a new stronger base. On the other theres no way to know how many of those 8.6M are sitting up there still that did not exit 9 months ago… It is ironic to me. Imagine buying last summer, holding this entire time, and selling 3 months before a highly derisked PDUFA. Crazy stuff. Need some buyers to show up to absorb this level…
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 9 at 10:44 PM
$UNCY One fun and oft overlooked detail from their annual report dated December 31, 2024. "In March 2023, we agreed with certain investors to modify our dividend policy to state that we intend to pay dividends to all stockholders on a quarterly basis in an amount of which the aggregate of all quarterly dividends shall equal at least seventy-five percent (75%) of our annual net cash flow from operations following the approval of Oxylanthanum Carbonate by the FDA if obtained, and the commencement of commercial sales." This is still the policy and will still happen once commercial sales begin in Q4.
3 · Reply
Boomer52
Boomer52 Mar. 9 at 12:26 PM
$UNCY Have you seen the latest March Presentation? Check it out. https://d1io3yog0oux5.cloudfront.net/_567c73cbe9cf1fbe989b1d7155ae0a49/unicycive/db/1912/17815/pdf/UNCY+Corporate+Deck++--++March+2026+%281%29.pdf
0 · Reply
Latest News on UNCY
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Feb 17, 2026, 9:15 AM EST - 26 days ago

Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Feb 4, 2026, 7:05 AM EST - 5 weeks ago

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile

Jan 29, 2026, 4:09 PM EST - 6 weeks ago

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 9:15 AM EST - 6 weeks ago

UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Jan 29, 2026, 7:05 AM EST - 6 weeks ago

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Dec 29, 2025, 7:05 AM EST - 2 months ago

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Dec 1, 2025, 1:41 PM EST - 3 months ago

Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Nov 25, 2025, 7:05 AM EST - 3 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 7:05 AM EST - 4 months ago

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 7:05 AM EST - 4 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Oct 30, 2025, 7:05 AM EDT - 4 months ago

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

Oct 28, 2025, 7:05 AM EDT - 4 months ago

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Oct 12, 2025, 8:52 AM EDT - 5 months ago

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

Oct 10, 2025, 6:56 PM EDT - 5 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

UNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th Deadline

Oct 10, 2025, 1:57 PM EDT - 5 months ago

UNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th Deadline

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

Oct 5, 2025, 11:43 PM EDT - 5 months ago

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Sep 30, 2025, 10:47 AM EDT - 5 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Sep 21, 2025, 8:16 AM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Aug 22, 2025, 10:45 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.

Aug 21, 2025, 7:05 AM EDT - 7 months ago

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately.

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately

Aug 20, 2025, 3:57 PM EDT - 7 months ago

Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Aug 18, 2025, 7:05 AM EDT - 7 months ago

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 14, 2025, 3:55 PM EDT - 7 months ago

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying

Jul 24, 2025, 5:36 PM EDT - 8 months ago

Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

Jul 24, 2025, 8:00 AM EDT - 8 months ago

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

Jul 19, 2025, 2:19 PM EDT - 8 months ago

UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 8, 2025, 8:30 AM EDT - 8 months ago

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 7, 2025, 7:00 AM EDT - 8 months ago

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Jun 30, 2025, 7:05 AM EDT - 9 months ago

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Jun 17, 2025, 7:00 AM EDT - 9 months ago

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Jun 10, 2025, 6:00 AM EDT - 9 months ago

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 13 at 7:56 PM
$UNCY UNCY analyst coverage snapshot (with creds): • Benchmark — Bruce David Jackson: Buy, PT $21 (Sep 15, 2025) • Guggenheim — Vamil Kishore Divan, M.D.: Buy, PT $46 (Dec 30, 2025) • H.C. Wainwright — Ramakant(h) Swayampakula, M.B.A., Ph.D.: Buy, PT $22 (Oct 29, 2025) • Lucid — Elemer Piros, Ph.D.: Buy, PT $63 (Nov 12, 2025) • NOBLE — Robert Michael LeBoyer: Outperform, PT $60 (Jan 30, 2026) • WestPark — Ed Arce: Buy, PT $72 (initiated Feb 19, 2026)
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 13 at 7:33 PM
$UNCY Continues to be overhead supply between $7 and $7.30. I expect there is more above that. Curious, has anyone seen data around the amount of accumulation at this level and higher?
0 · Reply
Mtango
Mtango Mar. 13 at 4:38 PM
$UNCY I spent over 3h using AI to generate the investment thesis in the post below. I welcome feedback on the bearish and bullish arguments. https://www.reddit.com/r/UNCY/comments/1rssasq/uncy_an_aigenerated_investment_thesis/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
1 · Reply
Mtango
Mtango Mar. 13 at 3:17 PM
$UNCY $UNCY TDAPA Risk Nobody’s Talking About Everyone assumes OLC gets TDAPA after approval. But there’s a real question about whether it qualifies under CMS rules. Under 42 CFR §413.234(e), drugs in an existing ESRD PPS functional category (which phosphate binders are) are EXCLUDED from TDAPA if their NDA is classified as Type 3 (new dosage form) or Type 5 (new formulation). OLC is a 505(b)(2) referencing Fosrenol. It shares substantially the same label. The approval is based on a bioequivalence study bridging to Fosrenol. The main difference? Smaller pills you swallow instead of chew. That screams Type 3 or Type 5 classification from FDA. (Continued below)
1 · Reply
zawojak
zawojak Mar. 13 at 12:04 PM
$UNCY possible $15 by december guys !!
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 12 at 11:36 AM
$CELC $UNCY $AXSM im coming
0 · Reply
AlbertSan
AlbertSan Mar. 11 at 11:03 PM
$UNCY ready with 20 calls for Jul
0 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 10 at 6:56 PM
$UNCY This level may take a bit to work out. Between 6-9-2025 and 6-24-2025 there were 8,678,970 shares bought above this price right before it dropped and CRL occurred… The sells each time we breach $7 are largely those of them who held on unloading to break even. On one side it is positive that we are placing the shares into stronger hands. It builds a new stronger base. On the other theres no way to know how many of those 8.6M are sitting up there still that did not exit 9 months ago… It is ironic to me. Imagine buying last summer, holding this entire time, and selling 3 months before a highly derisked PDUFA. Crazy stuff. Need some buyers to show up to absorb this level…
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 9 at 10:44 PM
$UNCY One fun and oft overlooked detail from their annual report dated December 31, 2024. "In March 2023, we agreed with certain investors to modify our dividend policy to state that we intend to pay dividends to all stockholders on a quarterly basis in an amount of which the aggregate of all quarterly dividends shall equal at least seventy-five percent (75%) of our annual net cash flow from operations following the approval of Oxylanthanum Carbonate by the FDA if obtained, and the commencement of commercial sales." This is still the policy and will still happen once commercial sales begin in Q4.
3 · Reply
Boomer52
Boomer52 Mar. 9 at 12:26 PM
$UNCY Have you seen the latest March Presentation? Check it out. https://d1io3yog0oux5.cloudfront.net/_567c73cbe9cf1fbe989b1d7155ae0a49/unicycive/db/1912/17815/pdf/UNCY+Corporate+Deck++--++March+2026+%281%29.pdf
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 6 at 6:56 PM
$UNCY Current Stock Price: $6.63 Contracts to trade: $7.5 UNCY Mar 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 38% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
GoldManStackz
GoldManStackz Mar. 5 at 11:47 PM
$IXHL $UNCY Except we already got phase 2 results and they were off the charts exceptional. Take your fud elsewhere femboy
1 · Reply
sjdjjsofdj
sjdjjsofdj Mar. 5 at 8:46 PM
$IXHL I am afraid that the early RS is due to expected bad results from the eop2. I bought $UNCY some months ago and they did the same (early RS before a CRL from the NDA submission).
4 · Reply
zawojak
zawojak Mar. 5 at 7:29 AM
$UNCY any time squeeze to $9 possible...have a FOMO 🚀
1 · Reply
dcajic2
dcajic2 Mar. 4 at 8:15 PM
$UNCY big profit and still Holding
1 · Reply
zawojak
zawojak Mar. 4 at 7:32 PM
$UNCY cash until end of 2027, smart management, careful with money, parthersgip wit Merck, over 82% institutional ownership 🚀🚀🚀 $30 recent TP.
2 · Reply
Neurogirl
Neurogirl Mar. 4 at 5:25 PM
$UNCY
0 · Reply
dcajic2
dcajic2 Mar. 3 at 10:42 PM
$UNCY holding on ina crazy market
0 · Reply
WhatsUpWhatsNot
WhatsUpWhatsNot Mar. 3 at 3:30 PM
$UNCY the markets are insanely ‘panicked’ this week..do your homework, focus on value forward, and be confident in your research..then execute a rare opportunity when found !
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 2 at 2:47 PM
$UNCY Continues today. 23,000 shares to drive from $6.79 to $6.65. 1,500 shares to push back to $6.75. Buyers are stacked… Sellers are a 10:1-20:1 minority. Institutions will not chase price as a first choice. They will wait for weak hands to come to them.
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Mar. 2 at 2:08 PM
$UNCY Days like this, with macro and geo political impacts, are exactly whats needed to filter out weak hands. Seeing somebody on IBKR selling for a 3% loss to Friday close overnight (small 1,000 share sale) is exactly who you do not want investing right now. Without shares transferred to stronger holders, in thin floats, it takes far too few stock hoppers to cap movement. Will be interested to see how detached overall (or if not at all) UNCY becomes from broader markets once volume returns between 9:30-10:30. If I were an institutional buyer this is the type of scenario (increased seller anxiety from holders who are not here for more than a few percent or from those few still trapped since last year trying to get back to even from pre PDUFA June 2025) where I am looking to accumulate.
0 · Reply
hofno2003
hofno2003 Mar. 2 at 8:07 AM
$UNCY This is what we may want to consider for UNCY's/OLC's investment thesis: "TDAPA allows for separate add-on paymentat 100% of ASPfor eligible new drugs for two years, followed by payment at 65% of ASP for three additional years based on the drug’s utilization". Thus, we have a very comfortable situation for 5 years at UNCY with OLC, approval in June given. Approval is more than likely, because efficacy and safety is ticked by the FDA, only CMC issues had to be and are resolved.
0 · Reply